Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway

PURPOSE: Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer. However, intrinsic and acquired resistance to gemcitabine inevitably occurs. The aims of this study were to assess the efficacy of the combination of src inhibition and gemcitabine in gemc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhen-Hua, Lin, Chen, Liu, Ming-Ming, Zhang, Jian, Tao, Zhong-Hua, Hu, Xi-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201240/
https://www.ncbi.nlm.nih.gov/pubmed/28036386
http://dx.doi.org/10.1371/journal.pone.0169230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201240/
https://www.ncbi.nlm.nih.gov/pubmed/28036386
http://dx.doi.org/10.1371/journal.pone.0169230

Ejemplares similares